|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/11/22 Achieve Life Sciences, Inc. 10-Q 6/30/22 60:7.3M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 2.15M
2: EX-31.1 Certification -- §302 - SOA'02 HTML 22K
3: EX-32.1 Certification -- §906 - SOA'02 HTML 20K
9: R1 Document and Entity Information HTML 75K
10: R2 Consolidated Balance Sheets (Unaudited) HTML 118K
11: R3 Consolidated Balance Sheets (Parenthetical) HTML 39K
(Unaudited)
12: R4 Consolidated Statements of Loss and Comprehensive HTML 69K
Loss (Unaudited)
13: R5 Consolidated Statements of Cash Flows (Unaudited) HTML 84K
14: R6 Consolidated Statements of Stockholder's Equity HTML 86K
(Unaudited)
15: R7 Nature of Business, Basis of Presentation and HTML 28K
Going Concern Uncertainty
16: R8 Accounting Policies HTML 23K
17: R9 Government Grant HTML 23K
18: R10 Intangibles HTML 62K
19: R11 License Agreements HTML 27K
20: R12 Fair Value Measurements HTML 132K
21: R13 Convertible Debt HTML 58K
22: R14 Common Stock HTML 207K
23: R15 Commitments and Contingencies HTML 128K
24: R16 Intangibles (Tables) HTML 62K
25: R17 Fair Value Measurements (Tables) HTML 149K
26: R18 Convertible Debt (Tables) HTML 70K
27: R19 Common Stock (Tables) HTML 186K
28: R20 Commitments and Contingencies (Tables) HTML 125K
29: R21 Nature of Business, Basis of Presentation and HTML 43K
Going Concern Uncertainty - Additional Information
(Detail)
30: R22 Government Grant - Additional Information HTML 31K
(Details)
31: R23 Intangibles - Additional Information (Detail) HTML 29K
32: R24 Intangibles - Components of Intangible Assets HTML 28K
(Detail)
33: R25 Intangibles - Estimated Future Amortization HTML 30K
Expense Related to Intangible Assets (Detail)
34: R26 License Agreements - Additional Information HTML 27K
(Detail)
35: R27 Fair Value Measurements - Additional Information HTML 24K
(Detail)
36: R28 Fair Value Measurements - Summary of Assets HTML 30K
Measured at Fair Value on Recurring Basis (Detail)
37: R29 Fair Value Measurements - Summary of Cash HTML 27K
Equivalents (Detail)
38: R30 Fair Value Measurements - Schedule of Aggregate HTML 27K
Fair Value of Principal Amount of Convertible Debt
(Detail)
39: R31 Convertible Debt - Additional Information HTML 73K
(Details)
40: R32 Convertible Debt - Schedule of Convertible Debt HTML 30K
Balance (Details)
41: R33 Common Stock - Authorized - Additional Information HTML 27K
(Detail)
42: R34 Common Stock - Issued and Outstanding Shares - HTML 57K
Additional Information (Detail)
43: R35 Common Stock - Stock Options - Additional HTML 100K
Information (Detail)
44: R36 Common Stock - Summary of Stock Options Activity HTML 34K
(Detail)
45: R37 Common Stock - Summary of Fair Value of Each Stock HTML 29K
Award for Employees and Directors (Detail)
46: R38 Common Stock - Summary of Share-Based Compensation HTML 27K
Expense for Stock Options, Restricted Stock and
Employee Share Purchase Plan (Detail)
47: R39 Common Stock - Restricted Stock Unit Awards - HTML 30K
Additional Information (Detail)
48: R40 Common Stock - Summary of Restricted Stock Unit HTML 37K
Award Activity (Detail)
49: R41 Common Stock - Employee Share Purchase Plan - HTML 24K
Additional Information (Detail)
50: R42 Common Stock - Summary of Outstanding Warrants HTML 52K
(Detail)
51: R43 Common Stock - Common Stock Warrants - Additional HTML 31K
Information (Detail)
52: R44 Commitments and Contingencies - Summary of HTML 25K
Contractual Obligations (Detail)
53: R45 Commitments and Contingencies - Additional HTML 68K
Information (Detail)
54: R46 Commitments and Contingencies - Summary of Future HTML 26K
Minimum Annual Lease Payments (Detail)
55: R47 Commitments and Contingencies - Summary of Other HTML 28K
Information Related to Leases (Detail)
58: XML IDEA XML File -- Filing Summary XML 109K
56: XML XBRL Instance -- achv-10q_20220630_htm XML 1.57M
57: EXCEL IDEA Workbook of Financial Reports XLSX 98K
5: EX-101.CAL XBRL Calculations -- achv-20220630_cal XML 110K
6: EX-101.DEF XBRL Definitions -- achv-20220630_def XML 496K
7: EX-101.LAB XBRL Labels -- achv-20220630_lab XML 967K
8: EX-101.PRE XBRL Presentations -- achv-20220630_pre XML 710K
4: EX-101.SCH XBRL Schema -- achv-20220630 XSD 150K
59: JSON XBRL Instance as JSON Data -- MetaLinks 288± 461K
60: ZIP XBRL Zipped Folder -- 0001564590-22-029122-xbrl Zip 350K
Exhibit 32.1
Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
I, John Bencich, Chief Executive Officer and Principal Executive and Financial Officer of Achieve Life Sciences, Inc. (the “Company”), certify, pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, that:
(1) the Quarterly Report on Form 10-Q of the Company for the three and six months ended June 30, 2022 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 780(d)); and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: August 11, 2022
|
|
|
/s/ John Bencich |
|
|
|
|
|
|
|
Chief Executive Officer (Principal Executive and Financial Officer) |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/11/22 | 8-K | ||
| For Period end: | 6/30/22 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 1/12/23 Achieve Life Sciences, Inc. 424B7 1:173K Donnelley … Solutions/FA 12/29/22 Achieve Life Sciences, Inc. S-3 4:276K Donnelley … Solutions/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/27/22 Achieve Life Sciences, Inc. 8-K:1,2,8,9 4/26/22 14:3.8M ActiveDisclosure/FA |